Myelodysplastic Syndrome
Conference Coverage
In MDS, transplant ups survival in elderly and may be reimbursed
Conference Coverage
Prevention of HMA failure a goal for high-risk MDS posttransplant
Conference Coverage
Are HMAS appropriate for posttransplant maintenance in acute leukemias?
Not yet, hematologist/oncologist tells colleagues at ALF meeting.
Conference Coverage
HMAs plus novel agents may improve outcomes in higher-risk MDS
Conference Coverage
For lower-risk MDS, treat ‘what bugs patients most’
News
FDA approves oral therapy for myelodysplastic syndromes, CMML
Under a priority review, the FDA approved a combination tablet for treatment of people with myelodysplastic syndromes or chronic myelomonocytic...
Feature
ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
Conference Coverage
Second transplant a good salvage option for children with ALL, AML, or MDS
From the Journals
Genetic analysis highlights value of germline variants in MDS, AML
Systematic genetic testing for DDX41 mutations may aid in clinical decision making for adults with MDS or AML.
Conference Coverage
Durable transfusion independence in MDS with imetelstat
AMSTERDAM – The telomerase inhibitor may also have disease-modifying properties, investigators suspect.
Conference Coverage
Antibody targeting ‘do not eat me’ signals is active in AML, MDS
CHICAGO – 5F9 plus azacitidine eradicated leukemia stem cells in responding patients, providing a mechanism for potential long-term durability.